Xiaohui Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaohui Ye has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hongshan Wei
Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China
3 shared publications - Junru Yang
Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3 shared publications - Lingling He
Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3 shared publications - Jia-Li Ma
Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
2 shared publications - Meixin Gao
Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
2 shared publications - Fan Xiao
Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 1 March 2020
- Published by Elsevier in Toxicology
- Vol. 433-434, 152411
Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury
- 1 March 2020
- Published by Elsevier in Toxicology
- Vol. 433-434, 152411
Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury
- Open Access
- 21 June 2019
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 1-9
Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy
The preventive effects of antiviral therapy to reduce rebleeding rate in patients with hepatitis B-related cirrhosis undergoing endoscopic treatment have not yet been reported. In this retrospective cohort study, 1139 patients with chronic hepatitis B with first acute variceal bleeding after endoscopic therapy from September 2008 to December 2017 were included. Among them, 923 who received and 216 who did not receive antiviral therapy were followed up for rebleeding. Cumulative rebleeding rate was calculated using the Kaplan-Meier method. Univariate and multivariate logistic regression analyses were performed to estimate the effects of antiviral therapy on rebleeding risk. The propensity score matched method and inverse probability of treatment weighting analysis were used to calculate the rebleeding rate between the antiviral and non-antiviral groups. The rebleeding rates were 40.5, 60.7, 72.6, and 89.2% in antiviral group at 1, 2, 3, and 5 years, respectively. The corresponding rebleeding rates in the non-antiviral group were 54.2, 72.4, 84.4, and 93.3%, respectively. The multivariate logistic regression analysis revealed that antiviral therapy was an independent protective factor associated with rebleeding. Antiviral treatment significantly reduced rebleeding rate in patients with HBV-related cirrhosis who received endoscopic treatment after the first variceal bleeding.
- 21 June 2019
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 1-9
Open AccessAntiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy
The preventive effects of antiviral therapy to reduce rebleeding rate in patients with hepatitis B-related cirrhosis undergoing endoscopic treatment have not yet been reported. In this retrospective cohort study, 1139 patients with chronic hepatitis B with first acute variceal bleeding after endoscopic therapy from September 2008 to December 2017 were included. Among them, 923 who received and 216 who did not receive antiviral therapy were followed up for rebleeding. Cumulative rebleeding rate was calculated using the Kaplan-Meier method. Univariate and multivariate logistic regression analyses were performed to estimate the effects of antiviral therapy on rebleeding risk. The propensity score matched method and inverse probability of treatment weighting analysis were used to calculate the rebleeding rate between the antiviral and non-antiviral groups. The rebleeding rates were 40.5, 60.7, 72.6, and 89.2% in antiviral group at 1, 2, 3, and 5 years, respectively. The corresponding rebleeding rates in the non-antiviral group were 54.2, 72.4, 84.4, and 93.3%, respectively. The multivariate logistic regression analysis revealed that antiviral therapy was an independent protective factor associated with rebleeding. Antiviral treatment significantly reduced rebleeding rate in patients with HBV-related cirrhosis who received endoscopic treatment after the first variceal bleeding.